Skip to main content
padlock icon - secure page this page is secure

Open Access Analysis of pathogenic bacteria and drug sensitivity on the infants with dacryocystitis

Download Article:

The full text article is available externally.

The article you have requested is supplied via the DOAJ. View from original source.

This article is Open Access under the terms of the Creative Commons CC BY-NC-ND licence.

AIM: To analyze the pathogenic bacteria and drug sensitivity on infants with dacryocystitis and provide the basis for the rational drug use.

METHODS: Lacrimal sac secretions from 83 infants(86 eyes)with dacryocystitis were used to do bacterial cultures and drug sensitivity tests.

RESULTS:In all 86 eyes, specimens of 84 eyes were positive in bacterial culture, and the pathogenic bacteria positive rate was 97.7%. Totally 94 bacterial strains were isolated from lacrimal sac secretions. The positive rates of gram-positive bacteria were 71.3%(67 strains)and gram-positive bacteria were sensitive to rifampicin, levofloxacin and chloramphenicol. The positive rates of gram-negative bacteria were 28.7%(27 strains), and gram-negative bacteria were sensitive to levofloxacin, chloramphenicol, fusidic acid and ceftazidime.

CONCLUSION: Gram-positive bacteria are the preponderant pathogenic bacteria of dacryocystitis in infants, and the most common of which are streptococcus viridans and staphylococcus epidermidis. The results of drug sensitivity tests show that drug resistance rate of gram-positive bacteria are higher than that of gram-negative bacteria. Levofloxacin and chloramphenicol are effective to infants with dacryocystitis.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: Shaanxi Institute of Ophthalmology, Shaanxi Key Laboratory of Ophthalmology, Xi'an No.1 Hospital, Xi'an 710002, Shaanxi Province, China

Publication date: January 1, 2015

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more